SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
A new report by Public Citizen reveals that American consumers pay nearly twice as much for the 20 top-selling pharmaceutical drugs than the rest of the world combined. (Photo: Chris Potter/Flickr/cc)
'Eye-Popping Rip-Off': Americans Pay Nearly Double Rest of World Combined for Top Meds
"Drug corporations clearly are taking advantage... and abusing their monopoly privileges—and everyone in the U.S. is paying for it."
Sep 30, 2021
As public health advocates fumed over efforts by right-wing congressional Democrats to water down prescription drug pricing reforms proposed in their own party's flagship Build Back Better package, a report published Thursday by a leading progressive advocacy group revealed that Americans are paying nearly twice as much for the 20 bestselling medications as the rest of the world combined.
"Empowering Medicare to push back against inflated drug prices is the responsible and commonsense way to stand up to the industry's greed."
--Rick Claypool,
Public Citizen
The Public Citizen report, entitled United We Spend, compares U.S. revenue from the top 20 "blockbuster" drugs to global sales figures as reported by pharmaceutical companies in their annual U.S. Securities and Exchange Commission (SEC) filings, or foreign equivalents.
According to the analysis, U.S. sales of the top 20 medications totaled $101.1 billion in 2020, while sales of the same drugs totaled $57 billion in the rest of the world.
The report found that "drugs with significant sales revenue disparities include Gilead Sciences' HIV medication Biktarvy, which had U.S. sales revenue five times greater than the rest of the world; AbbVie's autoimmune disease drug Humira, which had U.S. sales revenue four times greater than the rest of the world; and Eli Lily's Type 2 diabetes drug Trulicity, Roche's multiple sclerosis drug Ocrevus, and Amgen and Pfizer's autoimmune disease drug Enbrel, all three of which had U.S. sales revenue more than triple the rest of the world."
Rick Claypool, a Public Citizen research director and co-author of the report, said Thursday that "this eye-popping rip-off Big Pharma is getting away with is an insult to the American people."
"Empowering Medicare to push back against inflated drug prices is the responsible and commonsense way to stand up to the industry's greed--which, certain members of Congress should be reminded, lawmakers in both parties have been promising to do for years," Claypool added.
A survey published Thursday by Invest in America and Data for Progress revealed that 73% of likely U.S. voters support allowing Medicare to negotiate the cost of prescription drugs.
However, Republican and some Democratic lawmakers have been fighting efforts to reduce prescription drug prices, and other reforms. For example, Sen. Kyrsten Sinema (D-Ariz.)--who campaigned on a promise to "lower prescription drug prices"-- has been one of the staunchest congressional opponents of allowing Medicare to leverage its tremendous purchasing power to negotiate lower medication prices.
As Common Dreams reported Wednesday, members of Congress have been the leading beneficiaries of Big Pharma largesse, as drugmakers and private health insurers have spent $171 million so far in 2021 on lobbying--the most of any industry.
In the House, three key Democrats blocking drug pricing reform--Reps. Scott Peters (Calif.), Kathleen Rice (N.Y.), and Kurt Schrader (Ore.)--have taken a combined $1.6 million from Big Pharma over the course of their careers. In the Senate, two leading Democratic opponents of robust pricing reform--Sinema and Sen. Tom Carper (Del.)--have received more than $1.2 million in career pharmaceutical industry campaign contributions.
Earlier this week, a group of 160 patient advocates from across the United States sent a letter to House Speaker Nancy Pelosi (D-Calif.) demanding that congressional Democrats include drug pricing reforms--especially allowing Medicare to negotiate prescription rates--in the $3.5 trillion Build Back Better budget reconciliation package.
"Millions of American families ration medicine to help pay the bills," said Peter Maybarduk, director of Public Citizen's Access to Medicines program. "Until now, the U.S. government has not even asserted power to help by negotiating more reasonable prices. Drug corporations clearly are taking advantage of that weakness, and abusing their monopoly privileges--and everyone in the U.S. is paying for it."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
As public health advocates fumed over efforts by right-wing congressional Democrats to water down prescription drug pricing reforms proposed in their own party's flagship Build Back Better package, a report published Thursday by a leading progressive advocacy group revealed that Americans are paying nearly twice as much for the 20 bestselling medications as the rest of the world combined.
"Empowering Medicare to push back against inflated drug prices is the responsible and commonsense way to stand up to the industry's greed."
--Rick Claypool,
Public Citizen
The Public Citizen report, entitled United We Spend, compares U.S. revenue from the top 20 "blockbuster" drugs to global sales figures as reported by pharmaceutical companies in their annual U.S. Securities and Exchange Commission (SEC) filings, or foreign equivalents.
According to the analysis, U.S. sales of the top 20 medications totaled $101.1 billion in 2020, while sales of the same drugs totaled $57 billion in the rest of the world.
The report found that "drugs with significant sales revenue disparities include Gilead Sciences' HIV medication Biktarvy, which had U.S. sales revenue five times greater than the rest of the world; AbbVie's autoimmune disease drug Humira, which had U.S. sales revenue four times greater than the rest of the world; and Eli Lily's Type 2 diabetes drug Trulicity, Roche's multiple sclerosis drug Ocrevus, and Amgen and Pfizer's autoimmune disease drug Enbrel, all three of which had U.S. sales revenue more than triple the rest of the world."
Rick Claypool, a Public Citizen research director and co-author of the report, said Thursday that "this eye-popping rip-off Big Pharma is getting away with is an insult to the American people."
"Empowering Medicare to push back against inflated drug prices is the responsible and commonsense way to stand up to the industry's greed--which, certain members of Congress should be reminded, lawmakers in both parties have been promising to do for years," Claypool added.
A survey published Thursday by Invest in America and Data for Progress revealed that 73% of likely U.S. voters support allowing Medicare to negotiate the cost of prescription drugs.
However, Republican and some Democratic lawmakers have been fighting efforts to reduce prescription drug prices, and other reforms. For example, Sen. Kyrsten Sinema (D-Ariz.)--who campaigned on a promise to "lower prescription drug prices"-- has been one of the staunchest congressional opponents of allowing Medicare to leverage its tremendous purchasing power to negotiate lower medication prices.
As Common Dreams reported Wednesday, members of Congress have been the leading beneficiaries of Big Pharma largesse, as drugmakers and private health insurers have spent $171 million so far in 2021 on lobbying--the most of any industry.
In the House, three key Democrats blocking drug pricing reform--Reps. Scott Peters (Calif.), Kathleen Rice (N.Y.), and Kurt Schrader (Ore.)--have taken a combined $1.6 million from Big Pharma over the course of their careers. In the Senate, two leading Democratic opponents of robust pricing reform--Sinema and Sen. Tom Carper (Del.)--have received more than $1.2 million in career pharmaceutical industry campaign contributions.
Earlier this week, a group of 160 patient advocates from across the United States sent a letter to House Speaker Nancy Pelosi (D-Calif.) demanding that congressional Democrats include drug pricing reforms--especially allowing Medicare to negotiate prescription rates--in the $3.5 trillion Build Back Better budget reconciliation package.
"Millions of American families ration medicine to help pay the bills," said Peter Maybarduk, director of Public Citizen's Access to Medicines program. "Until now, the U.S. government has not even asserted power to help by negotiating more reasonable prices. Drug corporations clearly are taking advantage of that weakness, and abusing their monopoly privileges--and everyone in the U.S. is paying for it."
From Your Site Articles
- 'Unbelievable': Half of New Drugs Launched in 2020-2021 Cost $150,000 or More Per Year ›
- 'Put Patients First': 70+ Groups Push Senate to Act on Sky-High Drug Prices ›
- While Lobbying to Kill Build Back Better, Pharma Hikes Costs of 866 Drugs ›
- Critics See Menendez Villainy Equal to Sinema's on Medicare Drug Pricing Fight ›
- Arizona Groups Demand Sinema 'Stop Obstructing' on Medicare Expansion ›
- 'Entirely Unsurprising': Merck Slammed for 4,000% Markup of Taxpayer-Funded Covid Drug ›
- Do Not 'Cave to Big Pharma': 60+ Groups Tell Schumer, Pelosi to Deliver on Drug Pricing Reform ›
As public health advocates fumed over efforts by right-wing congressional Democrats to water down prescription drug pricing reforms proposed in their own party's flagship Build Back Better package, a report published Thursday by a leading progressive advocacy group revealed that Americans are paying nearly twice as much for the 20 bestselling medications as the rest of the world combined.
"Empowering Medicare to push back against inflated drug prices is the responsible and commonsense way to stand up to the industry's greed."
--Rick Claypool,
Public Citizen
The Public Citizen report, entitled United We Spend, compares U.S. revenue from the top 20 "blockbuster" drugs to global sales figures as reported by pharmaceutical companies in their annual U.S. Securities and Exchange Commission (SEC) filings, or foreign equivalents.
According to the analysis, U.S. sales of the top 20 medications totaled $101.1 billion in 2020, while sales of the same drugs totaled $57 billion in the rest of the world.
The report found that "drugs with significant sales revenue disparities include Gilead Sciences' HIV medication Biktarvy, which had U.S. sales revenue five times greater than the rest of the world; AbbVie's autoimmune disease drug Humira, which had U.S. sales revenue four times greater than the rest of the world; and Eli Lily's Type 2 diabetes drug Trulicity, Roche's multiple sclerosis drug Ocrevus, and Amgen and Pfizer's autoimmune disease drug Enbrel, all three of which had U.S. sales revenue more than triple the rest of the world."
Rick Claypool, a Public Citizen research director and co-author of the report, said Thursday that "this eye-popping rip-off Big Pharma is getting away with is an insult to the American people."
"Empowering Medicare to push back against inflated drug prices is the responsible and commonsense way to stand up to the industry's greed--which, certain members of Congress should be reminded, lawmakers in both parties have been promising to do for years," Claypool added.
A survey published Thursday by Invest in America and Data for Progress revealed that 73% of likely U.S. voters support allowing Medicare to negotiate the cost of prescription drugs.
However, Republican and some Democratic lawmakers have been fighting efforts to reduce prescription drug prices, and other reforms. For example, Sen. Kyrsten Sinema (D-Ariz.)--who campaigned on a promise to "lower prescription drug prices"-- has been one of the staunchest congressional opponents of allowing Medicare to leverage its tremendous purchasing power to negotiate lower medication prices.
As Common Dreams reported Wednesday, members of Congress have been the leading beneficiaries of Big Pharma largesse, as drugmakers and private health insurers have spent $171 million so far in 2021 on lobbying--the most of any industry.
In the House, three key Democrats blocking drug pricing reform--Reps. Scott Peters (Calif.), Kathleen Rice (N.Y.), and Kurt Schrader (Ore.)--have taken a combined $1.6 million from Big Pharma over the course of their careers. In the Senate, two leading Democratic opponents of robust pricing reform--Sinema and Sen. Tom Carper (Del.)--have received more than $1.2 million in career pharmaceutical industry campaign contributions.
Earlier this week, a group of 160 patient advocates from across the United States sent a letter to House Speaker Nancy Pelosi (D-Calif.) demanding that congressional Democrats include drug pricing reforms--especially allowing Medicare to negotiate prescription rates--in the $3.5 trillion Build Back Better budget reconciliation package.
"Millions of American families ration medicine to help pay the bills," said Peter Maybarduk, director of Public Citizen's Access to Medicines program. "Until now, the U.S. government has not even asserted power to help by negotiating more reasonable prices. Drug corporations clearly are taking advantage of that weakness, and abusing their monopoly privileges--and everyone in the U.S. is paying for it."
From Your Site Articles
- 'Unbelievable': Half of New Drugs Launched in 2020-2021 Cost $150,000 or More Per Year ›
- 'Put Patients First': 70+ Groups Push Senate to Act on Sky-High Drug Prices ›
- While Lobbying to Kill Build Back Better, Pharma Hikes Costs of 866 Drugs ›
- Critics See Menendez Villainy Equal to Sinema's on Medicare Drug Pricing Fight ›
- Arizona Groups Demand Sinema 'Stop Obstructing' on Medicare Expansion ›
- 'Entirely Unsurprising': Merck Slammed for 4,000% Markup of Taxpayer-Funded Covid Drug ›
- Do Not 'Cave to Big Pharma': 60+ Groups Tell Schumer, Pelosi to Deliver on Drug Pricing Reform ›
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.